Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 2, 2008

View Archived Issues

Positive first-in-human results of Novartis' ATF-936 for the treatment of osteoporosis

Glucosamine analogue GN-1 has in vivo antiarthritic activity

Peptide vaccine ATX-MS-1467 safe and well tolerated in MS patients

Benefit of alefacept in moderate to severe atopic eczema

A.P. Pharma highlights positive phase III APF-530 results in preventing CINV

VaxInnate advances second flu vaccine candidate into clinical development

Prasugrel NDA review not yet completed

Indevus and FDA agree on data requirement for Nebido resubmission

Indevus and Teva sign agreement for pagoclone

IND submission for HA-Irinotecan

Shionogi extends HuCAL license agreement with MorphoSys

Cancer Research UK and Astex to develop new cancer treatment

Daiichi delays Japanese launch of pediatric influenza vaccine ActHIB until December 2008

FDA extends PDUFA action date for Ipsen's BLA for Dysport in cervical dystonia

Astellas submits sNDA to Japanese PMDA for Prograf in myasthenia gravis

Novel antiinfective agents disclosed in recent MicuRx and GSK patents

European Commission grants orphan drug status to Enzon's Oncaspar-IV

Recent Tibotec patents report novel therapeutic agents for HCV infection

New agents for treating neurological disorders disclosed in recent patent literature

Bayer's novel anticoagulant Xarelto receives European approval

European Commission adopts EMEA recommendations for Arcoxia 90 mg

Idera reports preliminary data from phase IIa IMO-2055 trial in RCC

Lilly initiates second global phase III trial for LY-450139 in AD

Ore Pharmaceuticals initiates clinical trial of ACE2 enzyme inhibitor GL-1001

R&D highlights from the UBS Global Life Sciences Conference in New York: Sangamo BioSciences

Tranzyme presents positive phase IIb results for ghrelin agonist TZP-101

Uric acid, a novel therapeutic approach in the treatment of acute stroke

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...